Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05957146
Other study ID # NL84115.018.23
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date August 2023
Est. completion date August 2024

Study information

Verified date July 2023
Source Amsterdam UMC, location VUmc
Contact Muriel PC Grooteman, MD PhD
Phone +3120 566 5990
Email mpc.grooteman@amsterdamumc.nl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this observational study is to gain insight into the kinetics of extracellular vesicles (EVs), derived from both in- (i.e. bio-incompatibility) and outside (tissue-injury) the extracorporeal circuit (ECC), during standard hemodialysis (HD) in adult prevalent end-stage kidney disease (ESKD) patients treated with HD. During a single HD session, blood samples for EV-assessment will be taken at several time points and at different sampling sites in the extracorporeal circuit (sampling point 1: before the rollerpump, arterial line; sampling point 2: after the rollerpump and before the dialyzer, sampling point 3: after the dialyzer, efferent line).


Description:

Hemodialysis (HD) is a lifesaving treatment for ESKD patients. Yet, apart from beneficial effects, HD has adverse consequences, which, apart from rapid osmolality and electrolyte shifts, results from the bio-incompatibility (BI) of the extra-corporeal circuit (ECC) and intradialytic hypotension (IDH) as well. While BI arises within the ECC due to the contact between circulating blood cells and the foreign materials of the lines and dialyzer, IDH-induced tissue injury (TI) originates within the body of the patients. Activated cells can be detected by upregulation of cell surface markers and release of degradation products. Substances which are smaller than the pores of dialyzer-membranes may pass this barrier and, thus, become undetectable in blood. Various cell types shed small particles upon activation an/or injury, so called extracellular vesicles (EVs). These EVs, which are shed by various cell types upon activation and/or injury, contain various proteins and are too large to travers dialyzer membranes. Their assessment requires strict and standardized collection and handling of blood samples. In previous HD research, both pre-analytical circumstances and analytic methods were insufficiently standardized, precluding solid conclusions. Both the contact between circulating blood cells and the ECC, and recurrent IDH, predispose to micro-inflammation and cell activation, which are related to morbidity and mortality. Hence, when analysed properly, the measuring of EVs might be a valuable tool to assess dialysis-induced adverse side-effects, not only in the dialyzer but also in the body, which, when occurring repeatedly, may influence survival. In a recent study, we found an increase in EVs during treatment with different dialysis modalities. However, EVs were only assessed before and after dialysis. Hence, in the present study, we aim to assess the kinetics of EVs in routine HD.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 6
Est. completion date August 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age >18 years - Stable clinical situation: free of infection, no recent admission - HD >3 months - Haemoglobin level >6,2 mmol/L - Residual diuresis <200mL/24h - Willing and able to give written informed consent. Exclusion Criteria: - Active infection, malignancy, auto-immune disease, or treatment with immunosuppressive medication. - Allergy to polysulfone dialysers - Life expectancy <3 months due to non-renal disease - Access recirculation

Study Design


Intervention

Device:
Routine hemodialysis
Dialyzers: Cordiax FX80 dialyzers; membrane material HelixonePlus (polysulfone); (Fresenius Medical Care Bad Homburg, Germany) Dialysis machines: Baxter Gambro AK 98 (Gambro Lundia AB, Lund, Sweden; part of Baxter Healthcare Corporation) Needles for vascular access: Nipro SafeTouch dialysis cath 1.6x25 mm (16G) or 1.9x25 mm (15G); or Nipro SafeTouch Tulip needles (15G; all Nipro Medical Europe Mechelen, Belgium) Ultrapure dialysis fluids (less than 0.1 colony forming units/ml, less than 0.03 endotoxin units/ml) will be mixed with AC-F 219/1 or 213/4 liquid acid concentrates and BiBag dry bicarbonate concentrate. Hence, the electrolyte composition of the dialysis fluid will be: Na 138-142 mmol/L; K 2.0-3.0 mmol/L; HCO3 26-35 mmol/L; Ca 1.25-1.50 mmol/L; Mg 0.5 mmol/L; Cl 108.5-109 mmol/L; glucose 5.6 mmol/L; acetate 3 mmol/L. Dialysate flow rate will be 500 mL/min. Anticoagulation: nadroparin.

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Amsterdam UMC, location VUmc Amsterdam UMC, location AMC, Dianet Dialysis Centers

Outcome

Type Measure Description Time frame Safety issue
Primary Intradialytic change in the concentration of extracellular vesicles from specific cell types Blood cell-derived EVs: platelets: CD61+, activated platelets: CD61+/CD62p+; erythrocytes: CD235a+; leukocytes CD45+; and endothelium-derived EVs: CD144+, activated endothelium CD62e+; myocardium and endothelium-derived: Connexin-43+ will be measured at different sampling sites (sampling point 1: before the roller pump, arterial line; sampling point 2: after the rollerpump and before the dialyzer, sampling point 3: after the dialyzer, efferent line). 4 hours (=one dialysis treatment); assessed at the following time points: 0 minutes (start of dialysis), 30 min, 60 min, 120 min, 180 min, 235 minutes
Secondary Intradialytic blood pressure Change in systolic and diastolic blood pressure (mmHg) during dialysis 4 hours (=one dialysis treatment); measured 4x/hour
Secondary Hematocrit (Ht) the volume percentage of red blood cells (RBCs) in blood 4 hours (=one dialysis treatment); measured three times (at the start (0 minutes), half way (120 minutes) and at the end (240 minutes))
Secondary High sensitive CRP (hsCRP) Marker of inflammation 4 hours (=one dialysis treatment); measured once at the start of dialysis (0 minutes)
Secondary White blood cell (WBC) count Total white blood cell count and differential count 4 hours (=one dialysis treatment); measured once at the start of dialysis (0 minutes)
Secondary Platelet count Number of platelets in blood 4 hours (=one dialysis treatment); measured once at the start of dialysis (0 minutes)
See also
  Status Clinical Trial Phase
Completed NCT02235571 - iChoose Decision Kidney Aid for End-Stage Renal Disease Patients N/A
Active, not recruiting NCT05027074 - Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007) Phase 2
Completed NCT03582592 - Fluid Distribution Timetable on Adherence to Fluid Restriction of Patients With End-Stage Renal Disease on Hemodialysis N/A
Completed NCT02694068 - Biological Determinants of Peritoneal Dialysis
Not yet recruiting NCT02832505 - Applications of MRI in Kidney Disease
Not yet recruiting NCT02590081 - Effect of Sodium Rinsing Fluid on Blood Pressure and Interdialytic Weight Change in Hemodialysis Patients Phase 4
Completed NCT01859884 - Optimizing Kidney Transplant Informed Consent N/A
Completed NCT00509236 - Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1) Phase 3
Completed NCT02009514 - Glucose Containing and Glucose Free Hemodialysate in Type 2 Diabetic Patients Phase 4
Not yet recruiting NCT06377293 - Effect of Dialysis-specific Therapeutic Diet on Biochemical Parameters in Dialysis Patients N/A
Completed NCT01863914 - Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula Phase 2
Completed NCT01528800 - Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients Phase 2
Withdrawn NCT06030050 - Animal Assisted Intervention for Hemodialysis Outpatients N/A
Completed NCT04610593 - Effects of a Mindfulness-based Intervention in Stress, Pain and Quality of Life in People Undergoing Hemodialysis N/A
Recruiting NCT05931276 - CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes Phase 3
Completed NCT00143741 - Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers Phase 1
Active, not recruiting NCT02755610 - Check List to Improve Patient Self-care and Product Defect Report in Continuous Ambulatory Peritoneal Dialysis N/A
Recruiting NCT03142529 - Traditional Chinese Medicine (TCM) Colon Dialysis Treats Non-dialysis End-Stage Kidney Disease Phase 1/Phase 2
Completed NCT02342119 - Increasing Equity in Transplant Evaluation and Living Donor Kidney Transplantation N/A
Recruiting NCT05614115 - Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD Phase 1